Drugs & Targets FDA approves penpulimab-kcqx for non-keratinizing nasopharyngeal carcinoma April 25, 2025Vol.51 No.16
Drugs & Targets FDA grants Breakthrough Therapy designation for B7-H3 CAR T-cell therapy for diffuse intrinsic pontine glioma April 25, 2025Vol.51 No.16
Trump administration seeks to slash NIH by roughly 40% as 27 institutes and centers are whittled down to eightNCI to remain intact, but its finances are uncertain; FDA is spared big cuts April 18, 2025Vol.51 No.15By Paul Goldberg
Regulatory News RFK Jr. urges FDA staff to resist “agency capture” by special interests and resist “deep state”Whistleblowers will be “honored” April 18, 2025Vol.51 No.15By Jacquelyn Cobb
TIL + pembro regimen achieves 24% response rate in solid epithelial tumors, marking a step forward in immunotherapy research April 18, 2025Vol.51 No.15By Jacquelyn Cobb
Guest Editorial What would Mary do?Trump’s actions call for Lasker-style advocacy April 18, 2025Vol.51 No.15By Kevin J. Cullen
Cancer Policy John Burklow replaced by Seana Cranston as NIH chief of staff April 18, 2025Vol.51 No.15
Cancer Policy Trump’s healthcare executive order could be a win for pharma April 18, 2025Vol.51 No.15
Cancer Policy Trump administration says Harvard funding freezes will spare affiliated hospitals April 18, 2025Vol.51 No.15
